2017
HDR Monotherapy in Prostate Cancer: Radiobiological Considerations When Determining Biologically Effective Dose in Clinical Trials
Tien C, Carlson D, Nath R, Chen Z. HDR Monotherapy in Prostate Cancer: Radiobiological Considerations When Determining Biologically Effective Dose in Clinical Trials. Brachytherapy 2017, 16: s31. DOI: 10.1016/j.brachy.2017.04.038.Peer-Reviewed Original Research
2012
On the Use of Biologically Effective Dose (BED) and Iso-Effective Dose (IED) in Radiobiological Evaluations of Permanent Brachytherapy With Proliferating Tumors
Chen Z, Nath R. On the Use of Biologically Effective Dose (BED) and Iso-Effective Dose (IED) in Radiobiological Evaluations of Permanent Brachytherapy With Proliferating Tumors. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s755. DOI: 10.1016/j.ijrobp.2012.07.2020.Peer-Reviewed Original Research
2010
Hypofractionation Results in Reduced Tumor Cell Kill Compared to Conventional Fractionation for Tumors With Regions of Hypoxia
Carlson DJ, Keall PJ, Loo BW, Chen ZJ, Brown JM. Hypofractionation Results in Reduced Tumor Cell Kill Compared to Conventional Fractionation for Tumors With Regions of Hypoxia. International Journal Of Radiation Oncology • Biology • Physics 2010, 79: 1188-1195. PMID: 21183291, PMCID: PMC3053128, DOI: 10.1016/j.ijrobp.2010.10.007.Peer-Reviewed Original ResearchConceptsTumor cell killingTumor hypoxiaCell killingRadiation fractionation schemesTumor biological effective doseBiological effective doseTumor cell killRegions of hypoxiaRadiotherapy regimenTreatment failureConventional fractionationNeck cancerStandard fractionationProstate cancerTumor cell populationFractionation schemeRadiation therapyTumor clonogensTumor oxygenationBlood vessels resultsCell killEffective doseAlternate fractionationResistant cellsHypoxia
2007
On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned 131Cs Prostate Brachytherapy
Chen ZJ, Deng J, Roberts K, Nath R. On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned 131Cs Prostate Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2007, 70: 303-310. PMID: 17980500, PMCID: PMC2289996, DOI: 10.1016/j.ijrobp.2007.09.007.Peer-Reviewed Original ResearchConceptsDose reductionProstate brachytherapyDose compensationLarge edemaBiochemical recurrence-free survivalRecurrence-free survivalSignificant dose reductionEffects of edemaSublethal damage repairAdditional irradiationPrescription doseProstate cancerIndividual patientsEdemaEdema evolutionPrescribed doseProstate edemaEffective doseRadiobiologic effectsBrachytherapyDoseProstate implantsDose responseImplants
2000
Dosimetric effects of needle divergence in prostate seed implant using and radioactive seeds
Nath S, Chen Z, Yue N, Trumpore S, Peschel R. Dosimetric effects of needle divergence in prostate seed implant using and radioactive seeds. Medical Physics 2000, 27: 1058-1066. PMID: 10841410, DOI: 10.1118/1.598971.Peer-Reviewed Original ResearchConceptsMinimum target doseIodine-125 implantsTarget doseDose coverageTumor biological effective doseTarget dose coverageBiological effective doseBase of prostateRadioactive seedsProstate seed implantsProstate seedPalladium-103Target volumeEffective doseDosimetric qualityDosePatient implantsDosimetric effectsSeed implantsProstateImplantsMagnitude of degradationActual implantationNeedle orientationActual configuration
1999
Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue beds